Rising HIV Prevalence Fuels Growth In The Egrifta (Tesamorelin Acetate) Market: A Key Driver Powering Egrifta (Tesamorelin Acetate) Market Growth In 2025

The Egrifta (Tesamorelin Acetate) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Egrifta (Tesamorelin Acetate) Market Size and Its Estimated Growth Rate?
The market size for egrifta (tesamorelin acetate) has experienced a HCAGR of XX in the past few years. Predictions indicate that it will rise from $XX million in 2024 to $XX million in 2025 with a compound annual growth rate (CAGR) of XX%. Factors contributing to this growth during the historical period include an increased awareness of HIV-related issues, a heightened demand for drug therapies, an uptick in antiretroviral therapy use, improvements in the quality of life, advances in medical research, and general awareness.

The market for egrifta (tesamorelin acetate) is predicted to experience XX (FCAGR) growth in the coming years, and is forecasted to become a $XX million business by the year 2029, at a compound annual growth rate (CAGR) of XX%. The expected growth during the forecast period can be credited to factors such as the increasing occurrence of chronic illnesses, the rise in the number of healthcare centers, the escalating demand for sophisticated health monitoring devices, a growth in metabolic disorder cases, and increasing awareness around disease treatment. Trends projected to rise during this period include an increase in the use of targeted treatments, comprehensive care plan integration, developments in personalized health treatments, enhanced patient assistance programs, and a surge in research activities.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20043

How Are Emerging Segments Shaping the Egrifta (Tesamorelin Acetate) Market Landscape?
The egrifta (tesamorelin acetate) market covered in this report is segmented -

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
3) By End-Users: Hospitals, Specialized Clinics, Home Care

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp

Which Growth Factors Are Influencing Egrifta (Tesamorelin Acetate) Market Expansion?
Growing instances of human immunodeficiency virus (HIV) will be a key factor propelling the expansion of the egrifta (tesamorelin acetate) market in the forthcoming period. This term 'HIV cases' typically refers to circumstances in which people become infected with HIV, progressively debilitating their immune system. The increasing emergence of HIV can partially be attributed to a lack of proper awareness and education regarding precautionary steps, including consistent use of condoms and routine checks, especially among populations at increased risk. Egrifta acts by triggering the secretion of growth hormone, aiding in the reduction of surplus visceral fats and bettering body composition, substantially enhancing the overall wellbeing and life quality of people living with HIV. As an example, the Minnesota Department of Health, a state health organization based in the US, reported in May 2024 that there were 324 new HIV diagnoses in 2023, indicating a 24% surge from 2022. Hence, the escalating occurrences of human immunodeficiency virus (HIV) cases are contributing to the growth of the egrifta (tesamorelin acetate) market.

Who Are the Dominant Players Across Different Egrifta (Tesamorelin Acetate) Market Segments?
Major companies operating in the egrifta (tesamorelin acetate) market include Theratechnologies Inc.

What Are the Major Trends Shaping the Adbry/Adtralza Market?
A major trend within the egrifta (tesamorelin acetate) market is centered on the development of advanced synthetic peptide medications, aimed at improving the efficacy of treatments for HIV-related lipodystrophy. Synthetic peptide medicines are purposefully engineered substances designed for precise therapeutic impact, either by replicating or augmenting the function of naturally produced peptides. For example, in December 2024, Theratechnologies Inc., a biopharmaceutical institution based in Canada, declared that they have recommenced the production of EGRIFTA SV. This comes after a voluntary closure of their contractor manufacturer's facility due to observations made during an FDA inspection. A newly made batch has gone through quality control and is awaiting sanction for release from the U.S. Food and Drug Administration (FDA) in the form of a prior approval supplement, with two more batches already in the pipeline. Inventory is being overseen by the company to fulfill patient demands until mid-January 2025 while closely coordinating with the FDA to avoid any potential shortage in 2025. Notably, EGRIFTA SV is exclusively available within the United States.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

Which Geographic Regions Are Expected to Dominate the Egrifta (Tesamorelin Acetate) Market in the Coming Years?
North America was the largest region in the egrifta (tesamorelin acetate) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Egrifta (Tesamorelin Acetate) Market?
2. What is the CAGR expected in the Egrifta (Tesamorelin Acetate) Market?
3. What Are the Key Innovations Transforming the Egrifta (Tesamorelin Acetate) Industry?
4. Which Region Is Leading the Egrifta (Tesamorelin Acetate) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.